MaxCyte stock falls as revenue and market value remain under pressure

Published on 09/23/2026 at 10:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MaxCyte stock traded at USD 1.17 on September 22, 2026, down 2.5 percent with a USD 120.24 million market value. Revenue was USD 33.03 million.

MXCT, US57777K1060, Illustration mit AI erstellt.

MaxCyte stock (ISIN US57777K1060) closed at USD 1.17 on the Nasdaq on September 22, 2026, down 2.5 percent from the prior close. The move leaves the company with a market capitalization of USD 120.24 million, while reported revenue stands at USD 33.03 million.

Small valuation and weak earnings

The latest available market overview listed MaxCyte at USD 1.17 and a one-year performance of minus 19.7 percent on September 22, 2026. The same overview showed net income of minus USD 44.63 million and earnings per share of minus USD 0.33, indicating that the company remains loss-making on the reported figures.

Revenue of USD 33.03 million compares with net income of minus USD 44.63 million, a difference of USD 77.66 million between sales and bottom-line result. That comparison is the central financial constraint for the stock: the quoted revenue base is small relative to the reported loss.

Analyst target implies a wide gap

According to MarketBeat on September 22, 2026, analysts' price target was USD 5.00, or USD 3.83 above the quoted share price of USD 1.17. The same page assigned MaxCyte a MarketRank of 2.9089 out of 5 stars.

The target-to-price comparison represents a gap of 327.4 percent relative to the September 22 closing price. It is an analyst reference rather than a forecast made in this article, and the negative earnings figure remains a material counter-factor to that valuation gap.

MaxCyte stock stays near low valuation levels

At USD 1.17 on September 22, 2026, MaxCyte had a market value of USD 120.24 million against reported revenue of USD 33.03 million. The quoted price-to-sales ratio was 3.81, while the price-to-earnings ratio was not applicable because earnings per share were negative.

For investors, the key comparison is therefore between the USD 5.00 analyst target and the company's reported loss of USD 44.63 million. The market data show a heavily discounted equity value, but the earnings figures also show why a higher valuation would depend on improved profitability.

Stock price and market value

MaxCyte stock closed at USD 1.17 on the Nasdaq on September 22, 2026, with a daily decline of 2.5 percent. Market capitalization was USD 120.24 million on that date, while the quoted revenue figure was USD 33.03 million.